Клиномир в тестовом запуске. Кто с нами с первых дней, получит отметку «С первых дней» в профиле и первым увидит новые возможности сайта.

Зарегистрироваться
Идёт Фаза III Россия

Netakimab; Placebo; Adalimumab

A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, Pharmacokinetics, and Immunogenicity of Netakimab in Children With Moderate to Severe Plaque Psoriasis

Номер протоколаBCD-085-16
ФазаФаза III
Участников по плану — во всех странах исследования140
Сроки08.08.2024 — 01.02.2028
Начало: 8 августа 2024Окончание: 1 февраля 2028
Пройдено 65% планового срока

Постоянная ссылка: https://clinomir.ru/trials/nct/NCT06640517/

Источник: ClinicalTrials.gov (U.S. National Library of Medicine). Что откуда

Простыми словами

Словарь терминов
  • Фаза III — большое исследование: новый препарат сравнивают со стандартным лечением или плацебо, чтобы доказать пользу и безопасность.
  • Исследование идёт.
  • Возраст участников: 6–18 лет. Остальные условия — в блоке «Кто может участвовать».
  • По плану участвуют 140 чел. во всех странах исследования.
  • Центров в реестре: 13 в 11 городах. Список — ниже на странице.
  • Плановое окончание — 02.2028.

Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.

Кто может участвовать

Возраст6–18 лет
ПолЛюбой
Здоровые добровольцынет

Главное из критериев

  • ИнфекцииВИЧ, гепатит B или C упомянуты в критериях невключения

Выбрано из текста реестра автоматически, по правилам — без ИИ. Решение об участии принимает врач центра по полному протоколу.

Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 10 · невключение: 36

Критерии включения

  • Written informed consent of the legal representative and the subject to participate in the study (the study subject signs the appendix to the information sheet for the legal representative of the clinical study subject with informed consent form).
  • For Stage 1 only: age ≥12 and <18 years at the time of randomization.
  • For Stage 2 only: age ≥6 and <12 years at the time of randomization.
  • A diagnosis of moderate to severe plaque psoriasis with a disease duration of the disease being at least 3 months before the signing of the ICF.
  • Subjects who are candidates for phototherapy or systemic therapy for psoriasis (including non-responders to systemic therapy or phototherapy), in the opinion of the Investigator, or who did not achieve adequate disease control with topical agents.
  • At the time of the screening examination, the body surface area affected by psoriasis is >10% of the body surface area (BSA), the Psoriasis Area and Severity Index (PASI) score is ≥12, and the static Physician's Global Assessment (sPGA) score is ≥3.
  • Subjects with the normal laboratory test results at screening.
  • Subjects with a negative whole blood IFN-γ release test.
  • The ability of the subject and his/her legal representative, in the Investigator's opinion, to perceive information and follow the Protocol procedures.
  • Willingness of subjects and their sexual partners of childbearing potential to use highly effective methods of contraception from the signing of the ICF to 12 weeks after the last dose of the investigational product. This requirement does not apply to subjects who have not reached sexual maturity or who have undergone surgical sterilization. The subject's legal representative must consent to the subject's use of contraception.

Критерии невключения

  • 1\. Erythrodermic, pustular, guttate psoriasis, drug-induced psoriasis or any other skin diseases (e.g. eczema) at screening that can affect/complicate the assessment of psoriasis treatment with the investigational product.
  • 2\. Use of the following medications:
  • Prior use of drugs based on monoclonal antibodies against interleukin-17 or its receptor.
  • Prior use of adalimumab.
  • Prior use of monoclonal antibodies or their fragments within 12 weeks before signing the ICF.
  • Use of systemic non-biological medicinal products including methotrexate, sulfasalazine, cyclosporine or acitretin within 4 weeks prior to the date of signing the ICF. If previously used systemic non-biologic drugs are discontinued for any reason, the screening period can be extended for up to 8 calendar weeks, during which new systemic non-biologic drugs are not prescribed.
  • Use of phototherapy (including selective phototherapy \[UV-B\] and photochemotherapy \[PUVA\]) less than 4 weeks before the date of signing the ICF.
  • Vaccination with live vaccines at any time within 12 weeks prior to signing the ICF or an expected need for such vaccination during the study.
  • 3\. Recurrent, chronic, or any other active infection in which, in the opinion of the Investigator, the investigational product may harm the study subject.
  • 4\. Sepsis or risk of sepsis. 5. Positive HIV-1 or HIV-2 test. 6. HBV/HCV infections (for details, see Section 6.5.7.2). 7. Established diagnosis or a history of immunodeficiency syndrome (e.g., severe combined immunodeficiency syndrome, T and B cell deficiency syndromes, chronic granulomatous disease), or an infection characteristic of an immunodeficiency (e.g., pneumocystis pneumonia, histoplasmosis or coccidioidomycosis) at the time of signing the ICF.
  • 8\. Diagnosis of tuberculosis, including a history of tuberculosis. 9. A clinically significant infection caused by the varicella-zoster virus within 12 weeks prior to signing the ICF.
  • 10\. Body temperature ≥38°C at the screening. These subjects may be re-screened, but not earlier than 4 weeks after the first screening.
  • 11\. Other concomitant medical conditions that continued at the time of the screening examination, which increase the risk of adverse events during the study or may affect the evaluation of psoriasis symptoms, mask, enhance, or alter the symptoms of psoriasis, or cause clinical or laboratory symptoms similar to those of psoriasis and confirmed by the source documentation:
  • Active inflammatory diseases or aggravation of chronic inflammatory diseases other than psoriasis.
  • Functional class III-IV stable angina of effort, unstable angina or a history of myocardial infarction within 1 year before signing the IC.
  • Moderate to severe cardiac failure (NYHA class III-IV).
  • Grade 2 hypertension.
  • A history of atopic asthma, angioedema.
  • Moderate to severe respiratory failure, Grade 3/4 chronic obstructive pulmonary disease.
  • Decompensated diabetes mellitus; decompensated hypothyroidism, decompensated thyrotoxicosis.
  • Significant systemic autoimmune diseases according to the Investigator.
  • A history of Crohn's disease, ulcerative colitis.
  • Any other underlying conditions (including but not limited to metabolism, hematology, renal, hepatic, pulmonary, neurological, endocrine, cardiac, and gastrointestinal disorders; infections) that may, in the Investigator's opinion, affect the course of psoriasis, affect the assessment of its symptoms, or put the subject using the study therapy at unacceptable risk.
  • 12\. Malignant and lymphoproliferative diseases, including lymphoma; symptoms indicating the development of a lymphoproliferative disease (such as lymphadenopathy and/or splenomegaly), except for those previously excluded by a biopsy.
  • 13\. History of allergic reactions (anaphylactic shock or allergy to 2 or more drugs).
  • 14\. Known allergy or intolerance to monoclonal antibody products or any components of the investigational product.
  • 15\. Major surgery within 30 days before the screening, or a major surgery scheduled at any time during the study.
  • 16\. Severe infections (including those that required hospitalization or parenteral antibacterial, antimycotic, or antiprotozoal agents) within 6 months prior to signing the ICF.
  • 17\. Use of systemic antibacterial, antimycotic, or antiprotozoal agents within 2 months before signing the ICF.
  • 18\. More than 4 episodes of respiratory infections over the past 6 months prior to signing the ICF.
  • 19\. Any concomitant diseases in which, in the Investigator's opinion, the study therapy may harm the subject.
  • 20\. Signs of premature puberty at the screening examination. 21. Pregnancy, breastfeeding, or planning pregnancy while participating in the study.
  • 22\. Any psychiatric disorder, including a history of severe depressive disorders and/or suicidal thoughts, which, in the opinion of the Investigator, may pose an excessive risk to the subject or affect the subject's ability to follow the Protocol.
  • 23\. Drug addiction, alcoholism, or abuse with drugs or other psychoactive substances (including a history of such disorders).
  • 24\. Simultaneous participation in other clinical studies, as well as previous participation in other clinical studies less than 3 months before signing the ICF, prior participation in this study.
  • 25\. Use of any other investigational products at the time of signing the ICF or less than 28 days before the planned date of signing the ICF or 5 half-lives (whichever is longer) before the date of signing the ICF.

Источник: ClinicalTrials.gov, NCT06640517 · запись обновлена в реестре 27 мая 2026.

Дизайн и результаты

ДизайнРандомизированное, четверное слепое, параллельные группы; цель — лечение
Участников по плану (все страны)140
Результатыбудут после окончания
Что измеряют — первичные конечные точки (2), вторичных — 13
  • Proportion of subjects achieving PASI75 — Week 12
  • Proportion of subjects achieving sPGA0/1 — Week 12

Цель исследования

The aim of the study is to evaluate the efficacy and safety of netakimab compared with placebo in a pediatric population of subjects over 6 years of age with moderate to severe plaque psoriasis. The study will have randomized, double-blind, placebo-controlled study with open-arm comparison.

Где проходит

13 центров в 11 городах

Откуда эта информация

  • ClinicalTrials.gov (U.S. National Library of Medicine) · NCT06640517 Официальный реестр (США) · загружено 9 ноября 2026
    Препарат, номер протокола, название, цель, фаза, статус, сроки, число участников, спонсор, центры

Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.

Изменения не сохранены

На этой странице есть несохранённые изменения. Если уйти со страницы, они пропадут.